Speakers

Expand/Collapse

Alejandro Amador
Head, Scientific Leader Discovery Biology Automation
GSK

Workshop B

July 16, 2019

11:30 am |
Introduction & Overview to 3D High Content Screening Approaches

Ana Zarubica
COO
Inserm Centre D’Immunoph- ENomique

Day Two

Thursday 13th December 2018

9:45 am | Q&A Panel - Strategy – Selection – Characterization

9:20 am | Immunoprofiling of Murine Tumor Models to Improve the Translational Prediction of Immune-Based Therapeutics

Andrew Rhim
Associate Director - Translational Research & Assistant Professor – Gastroenterology
MD Anderson Cancer Center

Chen Zhao
Clinical Fellow
National Institutes of Health

Corinne Reimer
Associate Director, In Vivo Pharmacology
AstraZeneca

Day One

Thursday 13th December 2018

5:20 pm | Q&A - Modelling Cancer Drug Resistance

4:30 pm | Translational Strategies to Overcome Primary, Acquired & Adaptive Resistance

Dan Powell
Director, Clinical Tumor Tissue Facility & Associate Professor
University of Pennsylvania

Day Two

Thursday 13th December 2018

9:45 am | Q&A Panel - Strategy – Selection – Characterization

8:55 am | Models to Understand the Mechanisms of Action of Cancer Biologic Therapies

Davy Ouyang
Executive Director
Crown Bioscience

Day One

Thursday 13th December 2018

10:10 am | Panel Discussion - The Changing Expectations of Model Requirements

8:55 am | Developing Human Target Knock-In Mouse Models for Immuno-Oncology Drug Discovery

Enrique Alvarez
Director - Preclinical Development
Kleo Pharmaceuticals Inc.

Esmaiel Jabbari
Professor
University of South Carolina

Workshop C

July 16, 2019

3:00 pm |
Considerations in Modelling the Microenvironment

Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi

Day Two

Thursday 13th December 2018

2:30 pm | Moderator Feedback Panel

Fred Roberts
Sales Manager
Fuji film Visual Sonics

Geeta Sharma
Scientific Fellow, Translational Research
Tesaro

Day Two

Thursday 13th December 2018

9:45 am | Q&A Panel - Strategy – Selection – Characterization

8:30 am | Providing Translational Support for TSR Programs

Hervé Luche
Scientific Director Immunophenotyping Unit
Inserm Centre D’Immunoph- ENomique

Day Two

Thursday 13th December 2018

9:45 am | Q&A Panel - Strategy – Selection – Characterization

9:20 am | Immunoprofiling of Murine Tumor Models to Improve the Translational Prediction of Immune-Based Therapeutics

Hongmin Chen
Principal Scientist
Merck

Day Two

Thursday 13th December 2018

2:30 pm | Moderator Feedback Panel

Jenni Bernoulli
COO
Pharmatest Services

Juan Delgado
Lead Data Scientist
Fuel3D

Keiji Furuuchi
Associate Director & Head of Immunotherapy & Preclinical Development
Eisai

Kerry Whalen
Director - Discovery & Translational Biology
Tarveda Therapeutics

Lindsey Crowley
Scientist EMD
Serono

Day Two

Thursday 13th December 2018

2:30 pm | Moderator Feedback Panel

Maryland Franklin
Vice President – Scientific Development
MI Bioresearch

Day One

Thursday 13th December 2018

4:05 pm | Syngeneic Models of Breast and Ovarian Cancers: Effects of Immune Modulatory Agents in Classically “Cold” Tumors

Mike Brehm
Professor
University of Massachusettes

Day One

Thursday 13th December 2018

10:10 am | Panel Discussion - The Changing Expectations of Model Requirements

9:20 am | Opportunities & Challenges in Utilizing Humanized Mice to Model Human T Cell Responses

Mithun Khattar
Scientist & Immuno- Oncology Lead
Takeda

Neil Michaud
Director, Translational Medicine
EpiZyme

Omid Ghasemi
Scientist I, Imaging
Takeda

Rhys Jones
Senior Director DMPK
Pfizer

Day Two

Thursday 13th December 2018

4:00 pm | Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response

3:10 pm | Challenges & Opportunities in Understanding Drug Exposure at The Site Of Action Within Pre-Clinical Tumor Models And The Potential Implications Of Transporter Mediated Efflux

Rick Huntress
Director of Commercial Business Development
The Jackson Laboratory

Day One

Thursday 13th December 2018

10:10 am | Panel Discussion - The Changing Expectations of Model Requirements

9:45 am | Addressing the Demand for Clinically Relevant Models in IO Research

Sarah Knutsen
Director, Preclinical Biology
Twentyeight-Seven Therapeutics

Day Two

Thursday 13th December 2018

2:30 pm | Moderator Feedback Panel

Shanthi Ganesh
Associate Director
Dicerna Pharmaceuticals Corp.

Shiva Kazerounian
Principal Scientist, In Vivo Pharmacology Lead
Berg Pharma

Workshop A

July 16, 2019

8:00 am |
Challenges, Insights & Future Directions for Experimental Models in Cancer Immunotherapy

Shuxi Qiao
Senior Scientist Internal Medicine Research Unit
Pfizer Inc.

Silvia Goldoni
Investigator & Head of Oncology Lab
Novartis

Stefan Jellbauer
Technical Liaison for Translational Applications
Mitra Biotech

Day One

Thursday 13th December 2018

5:20 pm | Q&A - Modelling Cancer Drug Resistance

4:55 pm | A Clinically-Predictive Ex-Vivo Tumor Modeling Platform for Drug Discovery and Development

Tseten Jamling
VP of Research and Development
Hera Biolabs

Yvonne Evrard
Operations Manager
National Institute of Health Sciences

Day Two

Thursday 13th December 2018

4:00 pm | Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response

3:35 pm | NCI’s Patient Derived Models Repository Quality Control and Preclinical Efforts

Daniel Gioeli
Associate Professor
University of Virginia

Natalia Malkova
Lab Head/ Principal Research Investigator
Sanofi

Natalia Malkova is a principal research investigator in In vivo Pharmacology Group at Sanofi. She received her Ph.D. degree in molecular biology from Engelhardt Institute of Molecular Biology, Russia. She then continued her postdoctoral training in immunology at California Institute of Technology. Interests include cancer immunotherapy, tumor mouse models for preclinical and translational research, tumor microenvironment.

Day One

Thursday 13th December 2018

8:30 am | Experiment with Immune Targeting Therapeutics Agents & Synthetic Mouse Model